Mammaglobin-A is a target for breast cancer vaccination
Samuel W Kim1, Peter Goedegebuure2, William E Gillanders2
1Department of Surgery, Washington University School of Medicine , St. Louis, MO, USA.
Oncoimmunology
|April 9, 2016
Abstract:
We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concurrently with neoadjuvant endocrine therapy, providing a unique opportunity to examine the impact of vaccination in the tumor microenvironment.


